About US
Contact us
-
Neopharma to make Merck Serono diabetes drug for Middle EastAs drugmakers search the horizon for new markets where they can get some growth and perhaps get a jump on the competition, the Middle East is looking increasingly attractive. At least Merck Serono thi2012/12/5
-
Health economics and outcomes research 'increasingly important to pharma'Pharmaceutical companies are increasingly setting aside funding for research on health economics and outcomes, a study suggests. Cutting Edge Information's latest report, entitled 'Health Economics a2012/12/4
-
TOT Biopharm opens new production facility in ChinaTOT Biopharm Company Ltd has opened a new factory in eastern China. Stage one of its new high-tech production factory complex in the Suzhou Industrial Park has now been completed, with an inauguration2012/12/4
-
Presidio, BioCryst call off $101 million mergerPresidio Pharmaceuticals is leaving BioCryst Pharmaceuticals ($BCRX) at the altar. The companies announced today that their $101 million marriage is off. What broke up the two, whose hepatitis C pipe2012/12/3
-
Gorsky gets it all at J&J, to replace Weldon as chairmanAlex Gorsky now has it all. The CEO of Johnson & Johnson ($JNJ) today was named chairman of the drug and consumer products company, replacing Bill Weldon, who is retiring from J&J after four2012/12/3
-
AbbVie to ring in 2013 as an independent drugmakerAbbVie has its final stamp of approval. Abbott Laboratories' ($ABT) directors endorsed the pharma unit's spinoff Wednesday, allowing AbbVie to ring in the new year as an independent company. Abbott2012/11/30
-
Ranbaxy's recall second in three months for its generic LipitorThe potential manufacturing glitches that Ranbaxy Laboratories has been having with generic Lipitor production are more complicated than initially suggested when the Indian generics maker ordered a re2012/11/30
-
Branded drug prices leap 13% in U.S., far outpacing inflationWhile the pharma industry worries about drug spending cuts around the world, companies can still take heart from the good old U.S. of A. Drugmakers raised branded prices by 13.3%, more than 6 times t2012/11/29
-
Beactica Extends Fragment-Based Discovery Research Services AgreementBeactica, the leading Swedish fragment-based drug discovery company, today announced that it has added a project under its ongoing research services agreement with Janssen Research & Development2012/11/29
-
Bayer, Regeneron get EU nod for Eylea, next stop JapanBayer and partner Regeneron ($REGN) have notched another win for Eylea, getting approval for the eye drug in Europe for treating wet age-related macular degeneration. Eylea is already approved in t2012/11/28